Cyclooxygenase-2 Expression in Canine Appendicular Osteosarcomas
Corresponding Author
Marie N. Mullins
Animal Cancer Center, Departments of Clinical Sciences, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, CO
Animal Cancer Center, 300 West Drake Road, Fort Collins, CO 80523-1620; e-mail: [email protected].Search for more papers by this authorSusan E. Lana
Animal Cancer Center, Departments of Clinical Sciences, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, CO
Search for more papers by this authorWilliam S. Dernell
Animal Cancer Center, Departments of Clinical Sciences, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, CO
Search for more papers by this authorGregory K. Ogilvie
Angel Care Cancer Center, California Veterinary Specialists, San Marcos, CA.
Search for more papers by this authorStephen J. Withrow
Animal Cancer Center, Departments of Clinical Sciences, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, CO
Search for more papers by this authorE.J. Ehrhart
Microbiology, Immunology, and Pathology, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, CO
Search for more papers by this authorCorresponding Author
Marie N. Mullins
Animal Cancer Center, Departments of Clinical Sciences, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, CO
Animal Cancer Center, 300 West Drake Road, Fort Collins, CO 80523-1620; e-mail: [email protected].Search for more papers by this authorSusan E. Lana
Animal Cancer Center, Departments of Clinical Sciences, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, CO
Search for more papers by this authorWilliam S. Dernell
Animal Cancer Center, Departments of Clinical Sciences, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, CO
Search for more papers by this authorGregory K. Ogilvie
Angel Care Cancer Center, California Veterinary Specialists, San Marcos, CA.
Search for more papers by this authorStephen J. Withrow
Animal Cancer Center, Departments of Clinical Sciences, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, CO
Search for more papers by this authorE.J. Ehrhart
Microbiology, Immunology, and Pathology, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, CO
Search for more papers by this authorPreviously presented as an abstract at the 23rd annual Veterinary Cancer Society meeting, Madison, WI, September 2003.
Abstract
Osteosarcoma is the most common primary bone tumor in dogs and it has a high mortality rate from distant metastatic disease. Targeted adjuvant therapies are needed to prolong currently achievable survival times. The role of cyclooxygenase-2 (COX-2) in carcinogenesis has been attributed to the production of prostaglandins and involvement in apoptosis, immune surveillance, and angiogenesis. COX-2 is up-regulated in a number of different human and animal epithelial tumors, but data about its function in mesenchymal tumors is lacking. The purpose of this study was to evaluate COX-2 expression in canine appendicular osteosarcomas and to identify if a relationship exists between the intensity of COX-2 expression and clinicopathologic outcome. Of 44 osteosarcomas analyzed, 34 (77.3%) were positive for COX-2 expression. Most of the positive cases (88%) had poor to moderate COX-2 staining. Dogs that had strong COX-2 expression had significantly decreased overall survival time (P= .0107). The median survival times for dogs with negative (n = 10), poor (n = 19), moderate (n = 11), and strong (n = 4) expression were 423, 399, 370, and 86 days, respectively. Additional studies are warranted to further evaluate COX-2 in osteosarcoma for its prognostic value and as a target for adjuvant therapy.
References
- 1 Dernell WS, Straw RC, Withrow SJ. Tumors of the skeletal system. In: SJ Withrow, EG McEwen, eds. Small Animal Clinical Oncology. Philadelphia , PA : WB Saunders; 2001: 378–401.
- 2 Withrow SJ, Powers BE, Straw RC, Wilkins RM. Comparative aspects of osteosarcoma, dog versus man. Clin Orthop Related Res 1991; 270: 159–167.
- 3 Spodnick GJ, Berg J., Rand WM, et al. Prognosis for dogs with appendicular osteosarcoma treated by amputation alone: 162 cases (1978–1988). J Am Vet Med Assoc 1992; 200: 995–999.
- 4 Straw RC, Withrow SJ, Richter SL, et al. Amputation and cisplatin for the treatment of canine osteosarcoma. J Vet Intern Med 1991; 5: 205–210.
- 5 Berg J., Weinstein MJ, Springfield DS, Rand WM. Response of osteosarcoma in the dog to surgery and chemotherapy with doxorubicin. J Am Vet Med Assoc 1995; 206: 119–124.
- 6 Chun R., Kurzman ID, Couto G., et al. Cisplatin and doxorubicin combination chemotherapy for the treatment of canine osteosarcoma: Preliminary findings. J Vet Intern Med 2000; 14: 495–498.
- 7 Williams CS, Mann M., DuBois RN. The role of cyclooxygenase in inflammation, cancer, and development. Oncogene 1999; 18: 7908–7916.
- 8 Mohammed SI, Coffman K., Glickman NW, et al. Prostaglandin E2 concentrations in naturally occurring canine cancer. Prostaglandins Leukot Essent Fatty Acids 2001; 64: 1–4.
- 9 Menter DG. Cyclooxygenase 2 selective inhibitors in cancer treatment and prevention. Expert Opin Investig Drugs 2002; 11: 1749–1764.
- 10 Sandler RS, Halabi S., Baron JA, et al. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl J Med 2003; 348: 883–890.
- 11 Knapp DW, Richardson RC, Bottoms DG, et al. Phase I trial of piroxicam in 62 dogs bearing naturally-occurring tumors. Cancer Chemother Pharmacol 1992; 29: 214–218.
- 12 Knapp DW, Richardson RC, Chan TCK, et al. Piroxicam therapy in 34 dogs with transitional cell carcinoma of the urinary bladder. J Vet Intern Med 1994; 8: 273–278.
- 13 Masferrer JL, Leahy KM, Koki AT, et al. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res 2000; 60: 1306–1311.
- 14 Thun MJ, Henley SJ, Patrono C. Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst 2002; 94: 252–256.
- 15 Vidal S., Kovacs K., Bell D., et al. Cyclooxygenase-2 expression in human pituitary tumors. Cancer 2003; 97: 2814–2821.
- 16
Soslow RA,
Dannenberg AJ,
Rush D., et al.
COX-2 is expressed in human pulmonary, colonic, and mammary tumors.
Cancer
2000; 89: 2637–2645.
10.1002/1097-0142(20001215)89:12<2637::AID-CNCR17>3.0.CO;2-B CAS PubMed Web of Science® Google Scholar
- 17 Mohammed SI, Knapp DW, Bostwick DG, et al. Expression of cyclooxygenase-2 (COX-2) in human invasive transitional cell carcinoma (TCC) of the urinary bladder. Cancer Res 1999; 59: 5647–5650.
- 18 Murata H., Kawano S., Tsuji S., et al. Cyclooxygenase-2 over-expression enhances lymphatic invasion and metastasis in human gastric carcinoma. Am J Gastroenterol 1999; 94: 451–455.
- 19 Shono T., Tofilon TJ, Bruner JM, et al. Cyclooxygenase-2 expression in human gliomas: Prognostic significance and molecular correlations. Cancer Res 2001; 61: 4375–4381.
- 20 Kulkarni S., Rader JS, Zhang F., et al. Cyclooxygenase-2 is over-expressed in human cervical cancer. Clin Cancer Res 2001; 7: 429–434.
- 21 Bae SH, Jung ES, Park YM, et al. Expression of cyclooxygen-ase-2 (COX-2) in hepatocellular carcinoma and growth inhibition of hepatoma cell lines by a COX-2 inhibitor, NS-398. Clin Cancer Res 2001; 7: 1410–1418.
- 22 Kham KN, Knapp DW, Denicola DB, Harris RK. Expression of cyclooxygenase-2 in transitional cell carcinoma of the urinary bladder in dogs. Am J Vet Res 2001; 61: 478–481.
- 23 Dore M., Lanthier I., Sirois J. Cyclooxygenase-2 expression in canine mammary tumors. Vet Pathol 2003; 40: 207–212.
- 24 McEntee MF, Cates JM, Neilsen N. Cyclooxygenase-2 expression in spontaneous intestinal neoplasia of domestic dogs. Vet Pathol 2002; 39: 428–436.
- 25 Tremblay C., Dore M., Bochsler PN, Sirois J. Induction of prostaglandin G/H synthase-2 in a canine model of spontaneous prostatic adenocarcinoma. J Natl Cancer Inst 1999; 91: 1398–1403.
- 26 Khan KM, Stanfield KM, Trajkovic D., Knapp DW. Expression of cyclooxygenase-2 in canine renal cell carcinoma. Vet Pathol 2001; 38: 116–119.
- 27 Pestilli de AImeida EM, Piche C., Sirois J., Dore M. Expression of cyclooxygenase-2 in naturally occurring squamous cell carcinomas in dogs. J Histochem Cytochem 2001; 49: 867–875.
- 28 Dickens DS, Kozielski R., Khan J., et al. Cyclooxygenase-2 expression in pediatric sarcomas. Pediatr Dev Pathol 2002; 5: 356–364.
- 29 Burry RW. Specificity controls for immunocytochemical methods. J Histochem Cytochem 2000; 48: 163–165.
- 30 Sabino MC, Ghilardi JR, Jongen JLM, et al. Simultaneous reduction in cancer pain, bone destruction, and tumor growth by selective inhibition of cyclooxygenase-2. Cancer Res 2002; 62: 7343–7349.
- 31 Raisz LG. Potential impact of selective cyclooxygenase-2 inhibitors on bone metabolism in health and disease. Am J Med 2001; 110: 43–45.
- 32 Moalic S., Liagre B., Le Bail JC, Beneytout JL. Dose dependant modulation of apoptosis and cyclooxygenase-2 expression in human 1547 osteosarcoma cells by NS-398, a selective cyclooxygenase-2 inhibitor. Int J Oncol 2001; 18: 533–540.
- 33 Denkert C., Winzer KJ, Muller BM, et al. Elevated expression of cyclooxygenase-2 is a negative prognostic factor for disease free survival and overall survival in patients with breast carcinoma. Cancer 2003; 97: 2978–2987.
- 34 Ristimaki A., Sivula A., Lundin J., et al. Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer. Cancer Res 2002; 62: 632–635.
- 35 Sheehan KM, Sheahan K., O'Donoghue DP, et al. The relationship between cyclooxygenase-2 expression and colorectal cancer. JAMA 1999; 282: 1254–1257.
- 36 Tomozawa S., Tsuno NH, Sunami E., et al. Cyclooxygenase-2 overexpression correlates with tumour recurrence, especially haematogenous metastasis, of colorectal cancer. Br J Cancer 2000; 83: 324–328.
- 37 Achiwa H., Yatabe Y., Hida T., et al. Prognostic significance of elevated cyclooxygenase 2 expression in primary, resected lung adenocarcinomas. Clin Cancer Res 1999; 5: 1001–1005.
- 38 Kim HJ, Wu HG, Park IA, Ha SW. High cyclooxygenase-2 expression is related with distant metastasis in cervical cancer treated with radiotherapy. Int J Radiat Oncol 2003; 55: 16–20.
Citing Literature
